

Department of Vermont Health Access Pharmacy Benefits Management Program DUR Board Meeting Agenda

June 18, 2019: 6:30 – 8:30 p.m.

	Julie 16, 2019. 0.30 – 8.30 p.iii.		
•	Executive Session	6:00 - 6:30	
•	Introductions and Approval of DUR Board Minutes (Public Comment Prior to Board Action)	6:30 - 6:35	
•	DVHA Pharmacy Administration Updates	6:35 - 6:40	
•	Medical Director Update	6:40 - 6:45	
•	Follow-up Items from Previous Meetings RetroDUR additional data: Use of Opioids for Chronic Pain	6:45 - 6:50	
•	RetroDUR/ProDUR Introduce: Appropriate Use of Asthma Controller Medications Data presentation: Adherence to Anti-retroviral Therapy for HIV	6:50 - 7:15	
•	Clinical Update: Drug Reviews (Public comment prior to Board action)	7:15-7:45	
	Biosimilar Drug Reviews None at this time		
	Full New Drug Reviews (Any new drug reviews that also fall within the Therapeutic Class review the Therapeutic Class Review) Krintafel® (tafenquine) Onpattro® (patisiran) Sympazan® (clobazam) Tegsedi® (inotersen) Tolsura® (itraconazole capsules) Ultomiris® (ravulizumab-cwvz) Yupelri® (revefenacin)	will be discussed during	
•	New Managed Therapeutic Drug Classes (Public comment prior to Board action) None at this time	7:45 -7:45	
•	Therapeutic Drug Classes – Periodic Review (Public comment prior to Board action)	7:45 - 8:30	

	 Immunologic Therapies for Asthma Multiple Sclerosis Agents 	
•	Review of Newly-Developed/Revised Criteria (Public comment prior to Board action) None at this time	8:30 - 8:30
•	General Announcements Selected FDA Safety Alerts None at this time	8:30 – 8:30

8:30

Hypoglycemics, Incretin Mimetics/Enhancers & SGLT-2 Inhibitors

Bone Resorption Suppression and Related Agents

Hypoglycemics, Insulin and Related Agents
Hypoglycemics, Meglitinides
Hypoglycemics, TZD Agents

Antifungals, Oral Antifungals, Topical

Adjourn